Verquvo

Verquvo (generic name: vericiguat) is an oral medication prescribed for adults with chronic heart failure symptoms classified as HFrEF (ejection fraction less than 45%.) Vericiguat is a novel drug that acts as a soluble guanylate cyclase (sGC) stimulator. It increases cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation and improved cardiac function. It is used primarily to reduce the risk of severe cardiovascular events leading to hospitalization for heart failure. Heart failure is when the heart is weak and cannot pump enough blood to the body. Patients with HFrEF can exhibit symptoms like shortness of breath, fatigue, reduced capacity to exercise, fluid retention (edema), and accelerated heartbeat.

Dosage

Verquvo comes in three strengths. The prescribing doctor will determine the dose and how it should be taken. The recommended starting dose is one tablet of 2.5 mg daily. The doctor will adjust the dose depending on how well it is tolerated during treatment. The dose will usually be increased after two weeks to one tablet of 5 mg daily and after two weeks up to the maximum of one tablet of 10 mg daily. If symptoms of low blood pressure are felt while taking Verquvo, this can cause dizziness and light-headedness, in which case the doctor may temporarily reduce the dose or halt treatment with Verquvo. Take one tablet at the same time each day with food. If you cannot swallow the tablet, you may crush it and mix it with water. Take this mixture immediately after preparing it. Do not exceed the recommended dose.